14 stories mentioning SNDAUpdated 9d ago
Every FINWIRES story that references SNDA, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.1%.The iShares Biotechnology ETF (IBB) was down 1%.In corporate news, Sonida Senior Living (SNDA) shares rose 0.4% after Baird upgraded the stock to outperform from neutral and raised its price target to $43 from $37.
Sonida Senior Living (SNDA) shares rose 1.1% in Friday trading after Baird upgraded the stock to outperform from neutral and raised its price target to $43 from $37.Trading volume stood at more than 389,000 shares, compared with a daily average of about 614,000.Price: $38.29, Change: $+0.40, Percent Change: +1.07%
Sonida Senior Living (SNDA) has an average rating of overweight and mean price target of $47.50, according to analysts polled by FactSet.
Michael Simanovsky, 10% Owner, Director, on August 28, 2026, sold 123,988 shares in Sonida Senior Living (SNDA) for $4,761,783. Following the Form 4 filing with the SEC, Simanovsky has control over a total of 13,523,652 common shares of the company, with 13,523,652 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1043000/000089534526000386/xslF345X05/form4.xml
Welltower (WELL) and other senior housing REITs could see stronger growth in 2027 as occupancy rises, pricing improves, margins expand, acquisitions add earnings, and companies shift more capital toward higher-growth senior housing assets, Morgan Stanley said in a note emailed Tuesday.Low new supply and faster growth in the population aged 80 and above should keep demand above 90% and potentially reach 95%, while healthy balance sheets could support more acquisitions and investment, Morgan Stanley said.The investment firm expects Welltower, Sonida Senior Living (SNDA), American Healthcare REIT (AHR) and Janus Henderson-backed senior housing platforms to benefit from higher occupancy, and continued operating improvements.Morgan Stanley added that the life science property market should recover gradually in 2027 as supply falls and demand improves, though leasing, occupancy and upcoming lease expirations remain risks for some landlords..Morgan Stanley kept Welltower at overweight and raised its price target to $251 from $215, while lifting Sonida Senior Living's target to $44 from $38 and keeping its equal-weight rating as it expects stronger earnings growth and better operating performance.Price: $241.88, Change: $+5.64, Percent Change: +2.39%
Sonida Senior Living (SNDA) has an average rating of overweight and mean price target of $47.50, according to analysts polled by FactSet.
Sonida Senior Living (SNDA) owner-operator model and favorable senior housing industry fundamentals position the company for continued growth, RBC Capital Markets said in a report Monday.After hosting the company's executives for a non-deal roadshow in Chicago last week, the firm said management expects resident rate growth to "remain healthy," supported by strong demand in "attractive suburban markets," high occupancy and investments in "resident experience," while the company's "Sonida Performance Insight Navigator" operating platform continues to improve labor efficiency and reduce employee turnover, according to the report.The company's management also said integration of the 69 communities acquired through the CNL Healthcare Properties transaction remains "on track," with $13 million in initial cost synergies already realized and its full first-year "synergy target" unchanged, the report said.RBC has an outperform rating on Sonida Senior Living and raised its price target to $48 from $45.Price: $39.67, Change: $+0.63, Percent Change: +1.63%
Healthcare stocks advanced late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each rising about 2%.The iShares Biotechnology ETF (IBB) increased 1.2%.In sector news, President Donald Trump said Tuesday that US Food and Drug Administration Commissioner Marty Makary is resigning, Bloomberg reported.In corporate news, West Pharmaceutical Services (WST) shares were down 3% after the company said in a regulatory filing its global operations were disrupted by a cyberattack.Alkermes (ALKS) shares jumped past 7% after the firm said Tuesday a late-stage trial of Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and secondary targets.Sonida Senior Living's (SNDA) recent stock decline was unwarranted given the broad-based strength in its Q1 results, RBC said in a note. RBC kept its outperform rating and raised its price target to $45 from $39. Shares eased 0.2%.Dr. Reddy's Laboratories (RDY) plans to launch a generic version of Novo Nordisk's (NVO) Ozempic this month in Canada, Bloomberg reported Tuesday, citing Chief Executive Erez Israeli. Dr. Reddy's shares fell 5.3%, and Novo rose 1.1%.
Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 2.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) climbing 2.2%.The iShares Biotechnology ETF (IBB) increased 1.4%.In corporate news, Alkermes (ALKS) shares jumped past 5% after it said Tuesday a late-stage trial evaluating its investigational Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and key secondary endpoints.Sonida Senior Living's (SNDA) recent stock decline was unwarranted given the broad-based strength in its Q1 results, RBC Capital Markets said in a note. RBC reiterated its outperform rating on the stock and raised its price target to $45 per share from $39. Sonida shares added 1.5%.Agios Pharmaceuticals (AGIO) shares rose 1% after it said Tuesday it has submitted a supplemental New Drug Application to the US Food and Drug Administration seeking accelerated approval of mitapivat for the treatment of sickle cell disease.
Sonida Senior Living's (SNDA) recent stock decline was unwarranted given the broad-based strength in its Q1 results, RBC Capital Markets said in a Monday research report.Robust costs controls driven by labor productivity gains, scheduling discipline, and real-time KPI dashboards are driving margin expansion, the analysts said.A stable cost structure combined with growing occupancy offers a compelling setup for incremental margins in the future, according to the note.The company's $16 million to $20 million year-one general and administrative expenses synergy target related to its merger with CNL Healthcare Properties remains on track, RBC said.RBC reiterated its outperform rating on the stock and boosted its price target to $45 per share from $39.Price: $37.57, Change: $+0.60, Percent Change: +1.64%
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Healthcare Select Sector SPDR ETF (XLV) declining 0.4%.The iShares Biotechnology ETF (IBB) was little changed.In corporate news, Zoetis (ZTS) shares fell 7.5% after BNP Paribas cut its price target to $146 from $185, following the company's Q1 results late last week.Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 3.7%.Sonida Senior Living (SNDA) shares fell 3.3% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered into a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3%.
Healthcare stocks were mixed Monday afternoon with the NYSE Healthcare Index rising 0.2% and the State Street Healthcare Select Sector SPDR ETF (XLV) little changed, paring earlier losses.The iShares Biotechnology ETF (IBB) increased 0.3%.In corporate news, Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 2.2%.Sonida Senior Living (SNDA) shares fell 3.6% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Three analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3.3%, and Merck added 1.2%.
Healthcare stocks declined Monday afternoon, with the NYSE Healthcare Index fractionally lower and the State Street Healthcare Select Sector SPDR ETF (XLV) down 0.2%.The iShares Biotechnology ETF (IBB) increased 0.4%.In corporate news, Sonida Senior Living (SNDA) shares fell 3.3% after it reported Q1 loss Monday of $2.39 per diluted share, wider than a loss of $0.77 a year earlier. Three analysts polled by FactSet expected a loss of $1.53.
Sonida Senior Living (SNDA) has an average rating of overweight and mean price target of $35.25, according to analysts polled by FactSet.
